ES2177964T3 - Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores. - Google Patents

Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.

Info

Publication number
ES2177964T3
ES2177964T3 ES97914312T ES97914312T ES2177964T3 ES 2177964 T3 ES2177964 T3 ES 2177964T3 ES 97914312 T ES97914312 T ES 97914312T ES 97914312 T ES97914312 T ES 97914312T ES 2177964 T3 ES2177964 T3 ES 2177964T3
Authority
ES
Spain
Prior art keywords
cells
activated
procedure
production
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97914312T
Other languages
English (en)
Inventor
Giulia Casorati
Paolo Dellabona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Science Park Raf SpA
Original Assignee
Science Park Raf SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Park Raf SpA filed Critical Science Park Raf SpA
Application granted granted Critical
Publication of ES2177964T3 publication Critical patent/ES2177964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBE UN PROCEDIMIENTO PARA LA PRODUCCION DE CELULAS T ACTIVADAS, ESPECIFICAS DE TUMORES, POR CO - CULTIVO, EX VIVO, DE CELULAS TUMORALES DE UN PACIENTE CON CELULAS T DE DICHO PACIENTE, Y QUE COMPRENDE LAS ETAPAS DE: I) INCUBAR LAS CELULAS TUMORALES CON UNA PRIMERA PROTEINA DE FUSION OBTENIDA A PARTIR DE UNA PROTEINA B7 Y UN ELEMENTO DE UN PAR BIOLOGICO DE FIJACION, Y UNA SEGUNDA PROTEINA DE FUSION OBTENIDA A PARTIR DE UN ANTICUERPO CONTRA UN ANTIGENO DE LA SUPERFICIE CELULAR Y EL OTRO ELEMENTO DEL PAR BIOLOGICO DE FIJACION; II) INHIBIR LA PROLIFERACION DE LAS CELULAS TUMORALES ANTES O DESPUES DE DICHA INCUBACION; III) CO - CULTIVAR LAS CELULAS TUMORALES CON LAS CELULAS T QUE DEBEN SER ACTIVADAS, HASTA QUE SE ALCANZA LA ACTIVACION DE LAS CELULAS T; IV) SEPARAR LAS CELULAS T ACTIVADAS DE LAS CELULAS TUMORALES, PROCEDIMIENTO QUE ES TOTALMENTE EFICIENTE Y PUEDE DESARROLLARSE DE MANERA SIMPLE.
ES97914312T 1996-03-30 1997-03-26 Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores. Expired - Lifetime ES2177964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96105157 1996-03-30

Publications (1)

Publication Number Publication Date
ES2177964T3 true ES2177964T3 (es) 2002-12-16

Family

ID=8222631

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97914312T Expired - Lifetime ES2177964T3 (es) 1996-03-30 1997-03-26 Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.

Country Status (8)

Country Link
US (1) US6399054B1 (es)
EP (1) EP0914416B1 (es)
JP (1) JP2000515364A (es)
AU (1) AU2160297A (es)
CA (1) CA2250394A1 (es)
DE (1) DE69713336T2 (es)
ES (1) ES2177964T3 (es)
WO (1) WO1997037004A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
ES2422193T3 (es) * 2002-06-28 2013-09-09 Life Technologies Corp Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1620564A4 (en) * 2003-04-18 2008-03-12 Cytovia Inc METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2335721A1 (en) * 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP7158104B2 (ja) 2016-07-15 2022-10-21 ビラクタ セラピューティクス，インク． Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
US20250154503A1 (en) 2022-01-14 2025-05-15 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
CN121909284A (zh) 2023-07-31 2026-04-21 图恩疗法股份有限公司 用于调节il-2基因表达的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0825888B2 (ja) * 1986-01-30 1996-03-13 フレッド ハッチンソン キャンサ− リサ−チ センタ− 免疫選択法
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
CA2167091A1 (en) * 1993-07-26 1995-02-02 Gordon J. Freeman B7-2: ctl a4/cd 28 counter receptor

Also Published As

Publication number Publication date
CA2250394A1 (en) 1997-10-09
DE69713336D1 (de) 2002-07-18
JP2000515364A (ja) 2000-11-21
DE69713336T2 (de) 2002-12-05
EP0914416B1 (en) 2002-06-12
US6399054B1 (en) 2002-06-04
WO1997037004A1 (en) 1997-10-09
AU2160297A (en) 1997-10-22
EP0914416A1 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
EP0957161A4 (en) METHOD FOR ACTIVATING HUMAN, ANTIGEN-ACTIVATING CELLS, ACTIVATED HUMAN, ANTIGEN-ACTIVATING CELLS, AND APPLICATIONS THEREOF
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
BG108492A (bg) Използване на въглероден окис за подобряване на резултатите при трансплантация на тъкани и органи и потискане на апоптозата
IT8022740A0 (it) Procedimento per la produzione di etanolo in forte concentrazione impiegando microorganismi immobilizzati.
KR900700130A (ko) 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법
EP2377548A3 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
BRPI9912227B1 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
DK0506884T3 (da) Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
DK1634949T3 (da) Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
ATE238553T1 (de) Krebsbehandlung
ES2007720A6 (es) Procedimiento de obtencion de una vacuna a base de flagelo bacterial.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
BR9609026A (pt) Composição processo para o tratamento do cáncer e de detecção para a produção de citicina por tumores para determinar a eficácia de um autólogo e kit diagnóstico para detecção para eficácia de compostos celulares autólogos
ATE90568T1 (de) Verwendung von zink- oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
ES8501630A1 (es) Un metodo para detectar o vigilar el estado de una condicion patologica humana que implica proteina de tejido conjuntivo.
ATE15693T1 (de) Zellkultur-verfahren.
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
ES2074983T3 (es) Procedimieto para el aislamiento de proteinas de membranas basales a partir de tejidos humanos y animales.